Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Helium-Free, Bench-Top MRI Scanner Draws Interest at Meetings

By BiotechDaily International staff writers
Posted on 21 May 2013
Ultra-compact, helium-free, preclinical, bench-top magnetic resonance imaging (MRI) scanners have been designed for preclinical imaging of lab animals.

The MR Solutions presented the new scanner at the American Association for Cancer Research (AACR) annual meeting in Washington DC (USA), on April 6-10, 2013, and the International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting in Salt Lake City (UT, USA), on April 20-26, 2013. The new technology spurred a lot of interest for the participants.

Dr. David Taylor, CEO of MR Solutions (Guildford, UK), said, “We were overwhelmed by the interest in this new scanner one of a range to follow soon. We were repeatedly told it was a game changer; producing high quality images without compromise and able to fit within an existing laboratory at a price which is more than competitive.”

MR Solutions, developed the world’s first commercial 3T scanner late in 2012, and in January 2013, introduced two larger bore machines to complete the range. The smaller two of the new scanners, the 16-cm bore, is available now (3T) while the other two machines—31-cm 3T and 72-cm 1.5T—will be available by the end of 2013; orders for these units are already in the works. The new range of three scanners will be able to scan from small to medium-sized animals.

The advantages of these technologic advances are: (1) the scanners provide excellent soft tissue contrast and molecular imaging capabilities. (2) They are very cost-effective as there is no need for all the cryogen cooling equipment. (3) Because they have a very small stray magnetic field, the scanners can be positioned close to other imaging equipment to enable multimodality imaging on the same subject. (4) Lastly, because of the lack of liquid helium cooling and required safety equipment, the scanners are easy to install and need no expensive building alterations.

Related Links:

MR Solutions



Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.